Searched for
UMIFENOVIR
Are fundamental tailwinds a stronger play than volatile markets? 6 mid-cap pharma stocks with an upside potential of over 22%- Mid-cap pharma space: Risk & opportunity are two sides of the same coin. 7 pharma stocks with upside potential of up to 41%
- Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%
- Medicine for bearish markets: 5 Indian pharma stocks with upside potential of up to 32%There are some sectors which are able to face bears in a better way. The reason, the operating matrix of those sectors is such that rising ...23 Oct, 2023, 01.39 PM IST
- Second & better attempt; 5 Indian pharma stocks with upside potential of up to 31%Both, in terms of bottomline and stock price performance, pharma stocks had been under pressure for a long time. Partly this under performa...11 Oct, 2023, 11.00 AM IST
- After a long winter finally some tailwinds; 6 pharma stocks with upside potential of up to 31%While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...19 Sep, 2023, 02.03 PM IST
- A Healthy Dose! 4 midcap pharma stocks with upside potential of up to 36%After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...29 Aug, 2023, 12.46 PM IST
- Finally out of the woods? 4 midcap pharma stocks with an upside potential up to 34 %Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...06 Aug, 2023, 12.57 PM IST
- On a path to recovery: 5 midcap pharma stocks with an upside potential up to 32%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized In...25 Apr, 2023, 01.31 PM IST
- On a path to recovery; 5 mid-cap pharma stocks with an upside potential up to 41%As the markets get jittery, select pharma stocks are back in focus. This tends to happen in bearish markets. Some of them are mid-sized Ind...22 Mar, 2023, 02.33 PM IST
- 6 midcaps that have beaten bearish & volatile markets can rise up to 42%, suggest analystsOnce again the US banks are at the center of a storm in equity markets. In such times, a few mid-cap stocks have been able to keep their he...21 Mar, 2023, 01.00 PM IST
- Midcaps with long term perspective; 9 stocks with high ROE & net profit marginMany investors, especially the ones sitting on cash are confused about what they should do with their existing stocks – buy the dip or not....05 Mar, 2023, 10.34 AM IST
- On a path to recovery; 7 mid-cap pharma stocks with an upside potential up to 47 %After the covid tailwinds got over, pharma stocks witnessed a phase of under-performance. However as the markets get jittery, select pharma...02 Mar, 2023, 01.04 PM IST
- No 'significant' benefit of favipiravir, umifenovir combination in Covid treatment: GlenmarkGlenmark had in May intimated the study to examine whether early administration of a combination of Favipiravir and Umifenovir enhances ant...09 Oct, 2020, 08.20 PM IST
- Drug firms get DGCI nod for Covid drug favipiravir despite inconclusive studyOn Tuesday, Hyderabad-based Biophore India Pharmaceuticals said it has received approval from the Drug Controller General of India (DGCI) t...14 Jul, 2020, 10.04 PM IST
- Glenmark Pharma cuts price of COVID-19 drug by 27% to Rs 75 per tabletIn a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab...13 Jul, 2020, 12.38 PM IST
- Glenmark launches COVID-19 drug after DCGI nod; MRP at Rs 103 per tabletThe company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer p...23 Jun, 2020, 09.36 PM IST
- COVID-19: CSIR institute to conduct clinical trials of antiviral drug UmifenovirThe drug has a good safety profile and acts by preventing entry of viruses into human cells and also by priming the immune system, accordin...19 Jun, 2020, 01.09 PM IST
- Lockdown, Day 63: India faces volley of shotsIndia is facing a volley of shots from all fronts as growth forecast is plummeting, and India faces a resurgent Chinese army at Ladakh. The...26 May, 2020, 06.54 PM IST
- Glenmark Pharma to study potential Covid-19 drug combinationThe study will look to enroll 158 hospitalized patients of moderate Covid-19 in India, the company added. Last month, Glenmark said it woul...26 May, 2020, 04.19 PM IST
Load More
